Joint Injections & Surgery: Options, Evidence & Limits

Before discussing an injection

Confirm the diagnosis, the joint and the intended role: temporary symptom relief, assistance with rehabilitation or another specific purpose. Bring diabetes, anticoagulant, infection and other medicine concerns to the discussion.

Original appointment prompt: “If this helps for a short period, how will we use that window to improve function?” Also ask what happens if it does not help and how success will be assessed. Do not interpret an injection as a guarantee that the underlying structural problem has been reversed.

Corticosteroid injections

NICE describes intra-articular corticosteroid relief in OA as short term, roughly two to ten weeks. That range is not a promise for every person. Suitability and repeat treatment decisions require assessment. NICE injection guidance.

Discuss infection risks, transient symptom changes, effects on blood glucose if relevant, and the timing of other procedures. A painful hot joint with fever needs assessment; it should not automatically be treated with an injection for a presumed flare.

Hyaluronic acid injections

NICE advises against offering intra-articular hyaluronan for OA; AAOS does not recommend its routine use in symptomatic knee OA. The current ACR summary is also unfavorable. Individual trial results or testimonials do not remove this guideline context. AAOS guideline; ACR summary.

Injected HA and oral HA supplements are different interventions. Evidence from one route cannot validate the other. Ask about absolute benefit beyond placebo, costs, injection reactions and how the proposed preparation matches research.

PRP: trial findings and guideline disagreement

In RESTORE, 288 adults aged at least 50 with mild-to-moderate knee OA received PRP or saline. At 12 months, pain fell by 2.1 versus 1.8 points on a 0–10 scale; the adjusted between-group difference was −0.4 points (95% CI −0.9 to 0.2), not statistically significant. Cartilage-volume change was also not significantly different. RESTORE trial.

Other studies have reported positive symptom outcomes, and preparations vary. AAOS describes possible benefit with limited evidence, while the 2026 ACR summary strongly recommends against PRP for knee and hip OA. The disagreement does not justify a regeneration guarantee. Ask about the exact protocol and relevant controlled trials.

Stem-cell and regenerative claims

FDA warns that marketed regenerative therapies have not been approved for orthopedic conditions such as OA and describes serious reported harms with unapproved products. Registration of a clinic or listing a study does not itself establish approval or efficacy. FDA patient information.

If a clinic advertises “cartilage regrowth,” request credible controlled human outcomes and clarify regulatory status. Do not rely on laboratory images, a before-and-after anecdote or a high price as evidence.

When a surgical discussion makes sense

A clinician can discuss replacement when joint symptoms substantially affect quality of life and suitable nonsurgical options have failed or are unsuitable. NICE advises individualized referral assessment, with personal risk discussion rather than blanket exclusion by age or body size. NICE referral recommendations.

A replacement consultation should cover expected symptom/function improvement, infection and clot risks, recovery support, rehabilitation, implant considerations and your goals. Ask which concerns are modifiable and what uncertainty remains. Surgery is not guaranteed to remove every source of pain.

Arthroscopy and recovery expectations

Routine arthroscopic lavage or debridement for osteoarthritis is discouraged by NICE. A different mechanical problem or injury requires its own assessment; “keyhole” does not make a procedure automatically useful or risk-free.

Original recovery-planning questions: Who will help with transport and daily tasks? What home setup is needed? What will the rehabilitation plan involve? How will work responsibilities be adapted? Preparation is part of the decision, not an afterthought.

When another delay or procedure may not help

The 2023 ACR/AAHKS timing guideline concerns patients with moderate-to-severe hip/knee disease who have tried ineffective nonoperative care and have chosen replacement. It conditionally advises against delaying solely to repeat physiotherapy, NSAIDs, walking aids or injections. It conditionally supports delay for nicotine reduction/cessation or better diabetes control; all recommendations had low or very low certainty. ACR/AAHKS: Optimal timing of hip and knee arthroplasty (2023).

This does not mean every painful joint needs surgery. First agree on the diagnosis, remaining suitable choices, likely benefit, risks and what matters to the patient. Ask the surgeon how your particular health conditions change the decision. An old scan or numerical pain score alone cannot supply that whole conversation.

An injection into a knee joint, around a shoulder tendon or into another structure is not the same procedure. Evidence and risks must match the target tissue; do not transfer an OA joint-injection result to every tendon problem.

Prepare for recovery before consenting

Hip recovery commonly takes months and includes early supported walking and a home programme; restrictions depend on the operation and the team’s instructions. Knee recovery can also continue for many months. A generic internet deadline is not clearance to drive or lift. NHS: Recovery from hip replacement; Hull University Teaching Hospitals NHS: Total knee replacement.

After surgery: know the escalation plan

Worsening wound redness, drainage, fever or increasing leg pain/swelling after replacement requires urgent advice from the care team or local medical service. Chest pain or breathing difficulty, especially with leg symptoms, needs emergency assessment for a possible pulmonary embolism. NHS: Hip-replacement complications and urgent help.

Ordinary postoperative soreness and swelling must be interpreted against the discharge plan and the trend. Do not assume a new severe symptom is “normal recovery,” and do not massage a suspected clot or change anticoagulant treatment independently.